. 2021 Mar 26;43(1):1–9. doi: 10.1038/s41401-021-00641-4

Table 1.

Studies investigating the outcome of Treg cells in murine models.

Study	Role for Treg cells	Model	Infarct volume	Treg depletion	Treg adoption	Outcome
Liesz et al. [34]	Protective	Mice: pMCAO	10–30 mm³	Anti-CD25 mAb	None	Infarct size was enlarged significantly 3 and 7 days after pMCAO
Liesz et al. [34]	Protective	Mice: pMCAO		None	CD4⁺CD25^- cells, total CD4⁺ cells, or Treg cells to RAG2^−/− mice 7 days before MCAO	Larger infarct size in the mice received CD4⁺CD25⁻ cells
Zhang et al. [35]	Protective	Mice: 60 min tMCAO	20–70 mm³	DEREG mice	IL-2/IL-2Ab	Decreased infarct size and improved sensorimotor outcomes 3 and 7 days after tMCAO
Kleinschnitz et al. [26]	Detrimental	Mice: 30 or 60 min tMCAO	60–90 mm³	DEREG mice	None	Reduced infarct volumes and better neurological function 1 day after IS
Kleinschnitz et al. [26]	Detrimental	Mice: 30 or 60 min tMCAO	5–10 mm³	DEREG mice	CD4⁺ CD25⁺ Treg cells, CD4⁺ CD25⁻ T cells, CD4⁺ CD25⁺ FoxP3⁺ Treg cells, or CD4⁺CD25⁻ FoxP3⁻ T cells to RAG2⁻^/−mice	Larger infarct size than RAG^−/−mice
Schuhmann et al. [36]	Detrimental	Mice: 30 min tMCAO	40–80 mm³	None	CD28 SA	Enhanced infarct size and worse functional outcomes
Schuhmann et al. [36]	Detrimental	Mice: 30 min tMCAO	30–40 mm³	Rag1^−/−mice or DEREG mice	CD28 SA	No significant difference in infarct size and behavior texting between treatment groups and controls
Ren et al. [37]	Neutral	Mice: 60 min tMCAO	~50% (Cortex; Hemisphere) ~90% (Striatum)^a	DEREG mice	None	No significant difference in infarct volumes and behavioral evaluations
Stubbe et al. [22]	Neutral	Mice: 30 min tMCAO	~40 mm³	Anti-CD25 mAb	None	No significant difference associated with Treg depletion

^aThis study analyzed the outcomes with infarct volume percent of the lesion.